ES2135934T3 - Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros. - Google Patents

Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.

Info

Publication number
ES2135934T3
ES2135934T3 ES96937390T ES96937390T ES2135934T3 ES 2135934 T3 ES2135934 T3 ES 2135934T3 ES 96937390 T ES96937390 T ES 96937390T ES 96937390 T ES96937390 T ES 96937390T ES 2135934 T3 ES2135934 T3 ES 2135934T3
Authority
ES
Spain
Prior art keywords
group
ilo
rent
fenile
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96937390T
Other languages
English (en)
Spanish (es)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2135934T3 publication Critical patent/ES2135934T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES96937390T 1995-11-09 1996-11-05 Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros. Expired - Lifetime ES2135934T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ES2135934T3 true ES2135934T3 (es) 1999-11-01

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96937390T Expired - Lifetime ES2135934T3 (es) 1995-11-09 1996-11-05 Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.

Country Status (29)

Country Link
US (1) US5929089A (enExample)
EP (1) EP0863897B1 (enExample)
JP (1) JP4263240B2 (enExample)
CN (1) CN1077891C (enExample)
AR (1) AR004708A1 (enExample)
AT (1) ATE181328T1 (enExample)
AU (1) AU707325B2 (enExample)
BG (1) BG63463B1 (enExample)
BR (1) BR9611311A (enExample)
CA (1) CA2236357C (enExample)
CO (1) CO4770968A1 (enExample)
CZ (1) CZ287268B6 (enExample)
DE (1) DE69602970T2 (enExample)
EE (1) EE03487B1 (enExample)
ES (1) ES2135934T3 (enExample)
GR (1) GR3030823T3 (enExample)
HU (1) HUP0001168A3 (enExample)
IL (1) IL124364A (enExample)
MX (1) MX9803696A (enExample)
NO (1) NO309606B1 (enExample)
NZ (1) NZ321626A (enExample)
PL (1) PL186204B1 (enExample)
RU (1) RU2167160C2 (enExample)
SI (1) SI0863897T1 (enExample)
SK (1) SK282335B6 (enExample)
TR (1) TR199800827T2 (enExample)
TW (1) TW371303B (enExample)
UA (1) UA50748C2 (enExample)
WO (1) WO1997017345A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
JP2002504896A (ja) * 1997-05-06 2002-02-12 サノフィ−サンテラボ ５−フェニル−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体およびそれらの５−ｈｔ４リガンドとしての使用
FR2763068B1 (fr) * 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
EP1112106B1 (en) 1998-09-18 2005-11-23 Alcon Manufacturing Ltd. Serotonergic 5ht2 agonists for treating glaucoma
JP2002542287A (ja) * 1999-04-28 2002-12-10 レスピラトリウス アクチボラゲット 医 薬
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
PT1313721E (pt) 2000-08-08 2006-06-30 Ortho Mcneil Pharm Inc Ariloxialquilaminas nao imidazoles como ligandos de receptor h3
AU8112101A (en) 2000-08-08 2002-02-18 Ortho Mcneil Pharm Inc Non-imidazole aryloxypiperidines
PT1311499E (pt) 2000-08-08 2006-07-31 Ortho Mcneil Pharm Inc Compostos biciclicos como ligandos do receptor h3
JP2005502623A (ja) 2001-07-02 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 置換ピペラジンおよびジアゼパン
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
EP1434765B1 (en) * 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
WO2003024928A2 (en) 2001-09-14 2003-03-27 Novo Nordisk A/S Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
JP2005511764A (ja) 2001-12-14 2005-04-28 アルコン，インコーポレイテッド 緑内障の処置のためのアミノアルキルベンゾフラン−５−オール化合物
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
BRPI0512046A (pt) 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
CN101321525B (zh) * 2005-12-01 2013-01-30 霍夫曼-拉罗奇有限公司 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物
KR20090040259A (ko) 2006-05-29 2009-04-23 하이 포인트 파마슈티칼스, 엘엘씨 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 ｈ3 수용체 안타고니스트로서의 용도
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
ME02107B (me) 2011-09-19 2015-10-20 Heteroaril jedinjenja kao ligandi 5-ht4 receptora

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
AU2435092A (en) * 1991-08-20 1993-03-16 Smithkline Beecham Plc 5-ht4 receptor antagonists
FI941178L (fi) * 1991-09-12 1994-03-11 Smithkline Beecham Plc 5-HT4-reseptoriantagonisteja
NZ246915A (en) * 1992-02-06 1996-05-28 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives, preparation and pharmaceutical compositions thereof
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
BG102412A (en) 1999-08-31
ATE181328T1 (de) 1999-07-15
NO982092L (no) 1998-06-29
AU7500196A (en) 1997-05-29
CZ142198A3 (cs) 1998-08-12
MX9803696A (es) 1998-09-30
AU707325B2 (en) 1999-07-08
GR3030823T3 (en) 1999-11-30
AR004708A1 (es) 1999-03-10
CN1077891C (zh) 2002-01-16
CN1202169A (zh) 1998-12-16
NO309606B1 (no) 2001-02-26
US5929089A (en) 1999-07-27
UA50748C2 (uk) 2002-11-15
TR199800827T2 (xx) 1999-02-22
HUP0001168A3 (en) 2001-07-30
CA2236357C (en) 2006-10-17
DE69602970T2 (de) 2000-01-20
NZ321626A (en) 1998-10-28
PL186204B1 (pl) 2003-11-28
PL326671A1 (en) 1998-10-12
EP0863897B1 (fr) 1999-06-16
NO982092D0 (no) 1998-05-07
BG63463B1 (bg) 2002-02-28
DE69602970D1 (de) 1999-07-22
CA2236357A1 (en) 1997-05-15
SK282335B6 (sk) 2002-01-07
EE03487B1 (et) 2001-08-15
SK59998A3 (en) 1998-11-04
IL124364A0 (en) 1998-12-06
RU2167160C2 (ru) 2001-05-20
CZ287268B6 (en) 2000-10-11
CO4770968A1 (es) 1999-04-30
HUP0001168A2 (hu) 2001-04-28
EE9800155A (et) 1998-12-15
SI0863897T1 (en) 1999-10-31
JP2000500125A (ja) 2000-01-11
WO1997017345A1 (fr) 1997-05-15
BR9611311A (pt) 1999-06-29
EP0863897A1 (fr) 1998-09-16
JP4263240B2 (ja) 2009-05-13
HK1016165A1 (en) 1999-10-29
IL124364A (en) 2001-08-08
TW371303B (en) 1999-10-01

Similar Documents

Publication Publication Date Title
ES2135934T3 (es) Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.
SV2003000882A (es) Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas ref.pca428-01cfp/bb
PA8491101A1 (es) Derivados de 4-fenil-piridin.
AR035793A1 (es) Compuesto de ciclopropilindol, formulacion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para la preparacion de compuestos intermediarios para su sintesis
ES2135414T3 (es) Antagonistas del receptor 5-ht4.
ES2157224T3 (es) Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1).
FI75559C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-aminopropoxiarylderivat.
ATE106401T1 (de) Benzodiazepin-analoge.
NO20026094D0 (no) Fusjonerte azepinderivater og deres anvendelse som antidiuretiske midler
EA200100535A1 (ru) Цементирующая композиция и ее применение для цементирования нефтяных скважин или подобных сооружений
MXPA00010060A (es) Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos.
EA200101223A1 (ru) Новые соединения, их применение и получение
DK1085896T3 (da) Somatostatinanaloger cykliseret med konformationelt begrænset skelet
PA8556301A1 (es) Compuestos pirimidina de anillo fusionado alquinilado
ATE328005T1 (de) Alle somatostatinrezeptorsubtypen-bindende somatostatinanaloge und deren verwendung
DK0626381T3 (da) Fremstilling af form 1 ranitidinhydrochlorid
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
ES2152237T3 (es) Pirazolo(4,3-c)piridinas, un procedimiento para su preparacion y su uso como inhibidores de la recaptacion de serotonina.
ES2089255T3 (es) N-(ariloxialquil)heteroaril-8-azabiciclo(3.2.1)octanos, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
Hurevich et al. Novel method for the synthesis of urea backbone cyclic peptides using new Alloc‐protected glycine building units
EP0725068A4 (en) INDOLDER DERIVATIVES
ATE168103T1 (de) Cholecystokininantagoniste
ES2171306T3 (es) Compuesto bajo la forma de isomero geometrico puro o de una mezcla de estos isomeros.
ES2165410T3 (es) Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
EP1123109A4 (en) CONTULAKIN-G, ITS ANALOGS AND USES THEREOF

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19981001

FG2A Definitive protection

Ref document number: 863897

Country of ref document: ES